Inhibrx's Cancer Breakthrough: A Billion-Dollar Race for INBRX-106

Inhibrx Biosciences has attracted attention from major pharmaceutical companies such as Merck & Co, Merck KGaA, and Ono Pharmaceutical for its experimental cancer drug INBRX-106. The San Diego-based biotech is evaluating a joint spin-off for INBRX-106 and a second cancer treatment, with a combined potential market value upwards of $9 billion.

INBRX-106, tested independently and with Merck's Keytruda, could significantly enhance the efficacy of the $30-billion-a-year immunotherapy, its high sales in 2025 demonstrating its prominence. While negotiations remain in preliminary stages, sources suggest the drug's valuation is contingent on imminent trial outcomes.

Inhibrx also plans to update on ozekibart, another promising drug with FDA fast track and orphan drug status, targeting Ewing sarcoma and colorectal cancer. With hopes for an FDA filing, ozekibart could reach valuation of about $1 billion, reinforcing Inhibrx's stronghold in cancer therapeutics.